Cite
APA Citation
Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019). sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International journal of neuroscience, 129, 119–128. http://access.bl.uk/ark:/81055/vdc_100078569126.0x000060